NFSG
CHRS icon

Newbridge Financial Services Group’s Coherus Oncology CHRS Stock Holding History

Newbridge Financial Services Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79
Closed -$82 – 1147
2024
Q3 		$82 Hold
79
– – ﹤0.01% 641
2024
Q2 		$137 Sell
79
-300
-79% -$604 ﹤0.01% 1056
2024
Q1 		$906 Hold
379
– – ﹤0.01% 1049
2023
Q4 		$1.26K Hold
379
– – ﹤0.01% 1006
2023
Q3 		$1.42K Buy
379
+79
+26% +$365 ﹤0.01% 1124
2023
Q2 		$1.28K Buy
+300
New +$1.77K ﹤0.01% 1188

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Newbridge Financial Services Group's CHRS Position: Q4 2024 in Review

Newbridge Financial Services Group sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 79 shares — an estimated $82 sold.

Newbridge Financial Services Group first reported a position in CHRS in Q2 2023 and held it in 6 quarters. The position peaked at $1.42K in Q3 2023. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Newbridge Financial Services Group reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 79 Coherus Oncology shares in Q4 2024, an estimated $82.
  • Newbridge Financial Services Group first reported a position in Coherus Oncology in Q2 2023 and held it in 6 quarters.
  • Newbridge Financial Services Group's Coherus Oncology position peaked at $1.42K in Q3 2023.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Newbridge Financial Services Group's 13F filing for Q4 2024, filed 28 Jan 2025.